Nurix Therapeutics, Inc. (NRIX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Arthur T. Sands	Chief Executive Officer, President & Director	1.21M	1962
Christine Ring	Chief Legal Officer, Secretary & Chief Compliance Officer	815,088	1965
Johannes Van Houte	Chief Financial Officer	848,254	1967
Gwenn Hansen	Chief Scientific Officer	866,275	1971
Jason Kantor	Chief Business Officer	0	N/A
John Kuriyan	Founder & Member of Scientific Advisory Board	0	N/A
Christopher Phelps	Senior Vice President & Head of Early Drug Discovery	0	N/A
Pasit Phiasivongsa	Chief Technical Officer	0	N/A
Arthur Weiss	Founder & Member of Scientific Advisory Board	0	N/A
Rita Kwong	Senior Accounting Manager	0	N/A

Name

Title

Pay

Year Born

Arthur T. Sands

Chief Executive Officer, President & Director

1.21M

1962

Christine Ring

Chief Legal Officer, Secretary & Chief Compliance Officer

815,088

1965

Johannes Van Houte

Chief Financial Officer

848,254

1967

Gwenn Hansen

Chief Scientific Officer

866,275

1971

Jason Kantor

Chief Business Officer

N/A

John Kuriyan

Founder & Member of Scientific Advisory Board

N/A

Christopher Phelps

Senior Vice President & Head of Early Drug Discovery

N/A

Pasit Phiasivongsa

Chief Technical Officer

N/A

Arthur Weiss

Founder & Member of Scientific Advisory Board

N/A

Rita Kwong

Senior Accounting Manager

N/A

Description

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.